Farrell Simon - 07 Mar 2023 Form 4 Insider Report for Trevi Therapeutics, Inc. (TRVI)

Role: Chief Commercial Officer
Signature: /s/ Christopher Galletta, attorney-in-fact
Issuer symbol: TRVI
Transactions as of: 07 Mar 2023
Net transactions value: +$9,581
Form type: 4
Filing time: 08 Mar 2023, 15:00:28 UTC
Previous filing: 16 Feb 2023
Next filing: 21 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TRVI	Common Stock	Options Exercise	$9,581	+18,750	+91%	$0.5110^*	39,400	07 Mar 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TRVI	Stock Option (right to buy)	Options Exercise	$0	-18,750	-25%	$0.000000	56,250	07 Mar 2023	Common Stock	18,750	$0.5110	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This option was granted on February 11, 2022. The 75,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026.